PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026

November 20, 2017 | By forimmediaterele | Filed in: Press Releases.

Travel & Tourism Industry release:

NEW YORK, Nov. 20, 2017 /PRNewswire/ — PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026

Summary

Read the full report: https://www.reportlinker.com/p05206659

Migraine is a complex neurological condition, characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

It is estimated that pharmaceutical sales in the migraine market were approximately US$3.3 Billion throughout the 7MM in 2016. The US contributed to over 70% of these sales, generating about US$2.3 billon, driven mainly by the sale of triptans (around US$1.5 Billion) and Botox (almost US$0.5 Billion). The only triptan to remain patented in the US in 2016 was Pfizer’s Relpax, which consequently is the highest-selling brand within this class.

Global migraine sales are expected to grow to around US$8.5 Billion by 2026, at a Compound Annual Growth Rate (CAGR) of over 10%. The growth will be driven by the launch of several late-stage pipeline products, particularly the calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) erenumab, galcanezumab, fremanezumab, and eptinezumab, developed by Amgen, Eli Lilly, Teva, and Alder respectively.

The major drivers of growth in the migraine market during the forecast period include –
– The launch and uptake of Eli Lilly’s lasmiditan and Allergan’s ubrogepant, which have novel mechanisms that satisfy unmet needs in the acute treatment market.
– The launch and uptake of Amgen’s erenumab, Eli Lilly’s galcanezumab, Teva’s fremanezumab, Alder’s eptinezumab, and Allergan’s atogepant, which are the first migraine-specific prophylactic treatments.
– The high annual cost of therapy for mAbs, which will mean they will generate high sales.
– A rising prevalence of migraine in the 7MM throughout the forecast period, which will lead to an increase in the diagnosed and treated population and will drive sales.

The report “PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026”, provides Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following –
– Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market
– Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
– Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Pfizer, Amgen, Eli Lilly, Teva, Alder Biopharmaceuticals, Merck & Co, Allergan, Zogenix, RedHill BioPharma, Desitin, Grupe JUSTE, Grunenthal.

Scope
– Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
– Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market
– Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
– Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Read the full report: https://www.reportlinker.com/p05206659

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/pharmapoint-migraine—global-drug-forecast-and-market-analysis-to-2026-300559655.html


Click here to read the full release with contact information on PR Newswire. Some releases are not in English.

To post and circulate your own press release on FIR and the eTN Network  please click here 

 


Comments are closed here.